An imbalance in bone formation relative to bone resorption results in the net bone loss that occurs in osteoporosis and inflammatory bone diseases. Although it is well known how bone resorption is stimulated, the molecular mechanisms that mediate impaired bone formation are poorly understood. Here we show that the time-and stage-specific inhibition of endogenous inhibitor of jB kinase (IKK)-nuclear factor-jB (NF-jB) in differentiated osteoblasts substantially increases trabecular bone mass and bone mineral density without affecting osteoclast activities in young mice. Moreover, inhibition of IKK-NF-jB in differentiated osteoblasts maintains bone formation, thereby preventing osteoporotic bone loss induced by ovariectomy in adult mice. Inhibition of IKK-NF-jB enhances the expression of Fos-related antigen-1 (Fra-1), an essential transcription factor involved in bone matrix formation in vitro and in vivo. Taken together, our results suggest that targeting IKK-NF-jB may help to promote bone formation in the treatment of osteoporosis and other bone diseases.
Postnatal skeletal growth and bone remodeling are highly coordinated processes that are primarily mediated by bone-forming osteoblasts and bone-resorbing osteoclasts [1] [2] [3] . Sex steroid deficiency after menopause, however, disrupts the balance between proper levels of bone formation and bone resorption and is a frequent cause of osteoporosis that is characterized by trabecular bone loss and increased risk of fracture. In osteoporosis, bone turnover is activated. Although bone formation is also enhanced, the bone formation rate is unable to match increased bone resorption, resulting in a net bone loss [4] [5] [6] [7] [8] . Also, bone formation is substantially compromised in inflammatory bone diseases such as arthritis and periodontitis 8 . Thus, understanding how the function of differentiated or mature osteoblasts is regulated in postnatal life is crucial for developing new and improved strategies for treating osteoporosis and inflammatory bone diseases.
The transcription factor NF-kB has a key role in inflammation and immune responses [9] [10] [11] [12] [13] . Growing evidence suggests that NF-kB signaling may be associated with metabolic diseases such as cachexia and diabetes [14] [15] [16] . Inhibition of IKK-b by specific peptides suppresses inflammatory bone loss by inhibiting osteoclast formation in an arthritis model, suggesting that NF-kB is a major target for the treatment of inflammatory bone diseases 15 . However, although the actions of NF-kB on osteoclastogenesis are well understood 16 , little is currently known about possible actions of NF-kB on osteoblast activity and bone formation, especially at the stage of postnatal skeletal growth and bone remodeling. In this study, we found that NF-kB activation in differentiated osteoblasts has an antianabolic effect on bone formation. We uncovered that NF-kB is a crucial factor responsible for impaired bone formation in osteoporosis. Specific inhibition of NF-kB in differentiated osteoblasts markedly prevented bone loss in ovariectomized mice by maintaining bone formation.
RESULTS

Inhibition of NF-jB promotes postnatal bone formation
Our initial intent was to investigate whether NF-kB also regulates osteoblast differentiation of mesenchymal cells, as NF-kB has been found to be essential in osteoclastogenesis 16 . Using two different NF-kB inhibitors, the dominant-negative mutant of IKK-g (IKK-DN, a C417R mutant of IKK-g) and superrepressor of IkBa (SR-IkBa) [17] [18] [19] [20] [21] , we found that the inhibition of NF-kB enhanced osteoblastic differentiation of mesenchymal C2C12 cells in vitro ( Supplementary Fig. 1 online) . However, owing to cell heterogeneity, it is very difficult to determine whether NF-kB affects osteoblast differentiation or function in vitro. Because gene ablation of major IKK-NF-kB components in mice results in an embryonic lethality 9 , it is impossible to use a general whole-body loss-of-function approach to examine the role of NF-kB in bone formation in various bone disease models. Given our results from mesenchymal cells, we decided to overcome the issue of embryonic lethality by using a tissue-specific gene expression approach. To do so, we took advantage of the osteoblast specificity of the bone g-carboxyglutamate protein-2 (Bglap2) promoter, which has been shown to be specifically activated in mature or differentiated osteoblasts [22] [23] [24] [25] . Our strategy was to use the Bglap2 promoter to drive IKK-DN in mature osteoblasts so that we could address whether NF-kB regulates mature osteoblast function without affecting osteoblast differentiation. We generated an IKK-DN construct under the control of the Bglap2 promoter. As expected, this construct was active in ROS17/2.8 osteoblast-like osteosarcoma cells but inactive in human embryonic kidney 293T cells ( Fig. 1a ). As a positive control, we expressed cytomegalovirus promoter driving IKK-DN in 293T cells ( Fig. 1a ). Subsequently, we used the Bglap2 construct to generate Bglap2-IKK-DN transgenic mice. Southern blot analysis revealed six founders expressing the transgene (Fig. 1b) . One of the founders, who expressed multiple copies of IKK-DN ( Fig. 1b) died shortly after birth. We maintained and used two different transgenic mouse lines (TG1 and TG2) derived from the surviving founder mice for further experiments. We detected IKK-DN proteins in transgenic mice in bone extracts but not in other tissues, including brain, liver and muscle ( Fig. 1c) . Moreover, we isolated calvarial cells from the two transgenic mouse lines. Whereas IKK-DN could not be detected in freshly isolated calvarial cells, IKK-DN was induced in cells from Bglap2-IKK-DN mice after 2 weeks, but not in cells from wild-type (WT) littermates ( Fig. 1d ). Not unexpectedly, the Bglap2-IKK-DN mouse had a phenotypically normal skeleton at birth ( Fig. 1e ).
Histological sections also confirmed that both Bglap2-IKK-DN mice and WT mice had normal bone structures (data not shown).
To examine whether inhibition of NF-kB in mature osteoblasts affects postnatal bone formation, we followed mouse skeletal growth of two transgenic founder lines by microradiography and microcomputed tomography (mCT). X-ray analysis showed that the size of Bglap2-IKK-DN mice was not markedly different from that of WT mice (data not shown). However, mCT analysis of the secondary spongiosa of distal femur metaphyses revealed that the bone mineral density (BMD) in the trabecular bone of Bglap2-IKK-DN mice was significantly higher compared with control mice at the ages of 2 and 4 weeks but not at the ages 2 and 6 months ( Fig. 2a,b) . Similarly, bone volumes were also higher in Bglap2-IKK-DN mice compared with control mice at the ages of 2 and 4 weeks but not at 2 and 6 months ( Fig. 2a,b ). However, there was no significant difference in cortical bone volume between the two groups (data not shown). Histological analysis of femurs and von Kossa staining of tibiae confirmed that the trabecular bone areas were substantially higher in 2-week-old Bglap2-IKK-DN mice compared with WT mice (Fig. 2c,d ), suggesting that inhibition of NF-kB enhances osteoblast function. The number of osteoblasts was similar in both Bglap2-IKK-DN mice and control mice, indicating that inhibition of NF-kB in mature osteoblasts does not affect osteoblast differentiation ( Fig. 2e) . To further confirm that the increased BMD is due to enhanced osteoblast function, we performed dynamic histomorphometric analysis over a 7-d period by labeling calcein, a well-known marker of bone formation. The bone formation rate in 2-week-old Bglap2-IKK-DN mice (477 ± 89 mm 3 per mm 2 per year) was 1.6-fold higher than that in control WT mice (299 ± 59 mm 3 per mm 2 per year) ( Fig. 2f ). Real-time RT-PCR revealed that the levels of bone matrix genes, including a-1 type 1 collagen (Col1a1), a-2 type 1 collagen (Col1a2), Bglap1 and Bglap2 (also known as osteocalcin, Ocn), secreted phosphoprotein-1 (Spp1), secreted acidic cysteine-rich glycoprotein (Sparc) and integrin-binding sialoprotein (Ibsp, also known as bone sialoprotein) were increased in bone extracts of 2-or 4-week-old Bglap2-IKK-DN mice compared to WT mice ( Fig. 2g ). To examine whether inhibition of NF-kB in differentiated osteoblasts affected osteoclasts indirectly, we performed a tartrate-resistant acid phosphatase (TRAP) assay. The number of osteoclasts was similar in both Bglap2-IKK-DN mice and WT mice (Fig. 2h ). The amount of serum TRAP5b, a sensitive marker of bone resorption and osteoclast function 5, 8 , was similar in both types of mice ( Fig. 2i ), suggesting that inhibition of NF-kB in mature osteoblasts does not affect osteoclast activation and bone resorption. The 2.3kilobase Col1a1 promoter is specifically activated in early differentiated osteoblasts 24 . To further confirm our results, we also used the 2.3-kilobase Col1a1 promoter to drive IKK-DN expression in osteoblasts in mice (Col1a1-IKK-DN mice). As in Bglap2-IKK-DN mice, BMD and trabecular bone formation in Col1a1-IKK-DN mice were also significantly enhanced, as determined by mCT and histological analysis ( Supplementary Fig. 2 online) . Taken together, these results suggest that inhibition of NF-kB in differentiated osteoblasts promotes bone formation in young mice.
NF-jB inhibition cell autonomously increases bone formation
To specifically determine whether inhibition of NF-kB enhanced bone-forming activity of osteoblasts by a cell-autonomous effect, we isolated primary calvarial cells from both Bglap2-IKK-DN mice and WT mice. Treatment with tumor necrosis factor (TNF) induced similar kinetics of IkBa phosphorylation and degradation in newly isolated calvarial cells from Bglap2-IKK-DN and WT mice ( Fig. 3a) .
To determine whether IKK-DN blocks NF-kB in differentiated osteoblasts, we grew cells in differentiation-inducing medium for 10 d and then treated them with TNF. Western blot analysis confirmed that the expression of IKK-DN was induced in differentiated osteoblasts ( Fig. 3b ). Although TNF induced phosphorylation and degradation of IkBa in WT cells, these events were markedly inhibited in differentiated Bglap2-IKK-DN cells (Fig. 3b) . Additionally, phosphorylation of the NF-kB p65 subunit at Ser536, a well-known site of IKK-b action 18 , was also substantially inhibited ( Fig. 3b) . Electrophoretic mobility shift assay (EMSA) and western blot analysis also confirmed that induction of IKK-DN inhibited the nuclear translocation of the NF-kB induced by TNF in Bglap2-IKK-DN cells ( Fig. 3c,d) . The supershift assay showed that NF-kB binding activities in differentiated osteoblasts mainly consisted of the p65 and p50 subunits (Fig. 3d) . Moreover, we found that osteoblast differentiation induced NF-kB binding activity in both Bglap2-IKK-DN cells and WT cells to a similar degree at the early time points. (Fig. 3e ). However, NF-kB binding activity was suppressed in Bglap2-IKK-DN cells 2 weeks after the induction of differentiation, validating the idea that IKK-DN inhibits NF-kB in differentiated osteoblasts ( Fig. 3e ). NF-kB binding activity in differentiated osteoblasts did not contain c-Rel and RelB, which are other NF-kB subunits ( Supplementary Fig. 3 online) . Upon induction of differentiation, bone matrix mineralization was more enhanced in Bglap2-IKK-DN cells compared to that in WT cells (Fig. 3f) . Consistently, real-time RT-PCR revealed that the expression of runt-related transcription factor-2 (Runx2) and Sp7 transcription factor (Sp7) was increased in Bglap2-IKK-DN cells (Fig. 3g) . The induction of Ocn and Ibsp was significantly higher in Bglap2-IKK-DN cells than in WT cells ( Fig. 3g) . In contrast, the expression of TNF superfamily member 11 (Tnfsf11) and TNF superfamily member 11b (Tnfrsf11b), which control osteoclast formation in these cells, was not changed in Bglap2-IKK-DN cells compared with control cells (Fig. 3h) . Additionally, we also isolated primary calvarial cells from both Col1a1-IKK-DN mice and WT mice. We found that calvarial cells isolated from Col1a1-IKK-DN mice also showed enhanced bone matrix gene expression and bone mineralization compared with WT cells ( Supplementary Fig. 4 online).
Next, we performed a rescue experiment to further rule out a possible nonspecific effect of IKK-DN. We overexpressed p65 to activate NF-kB and thus reverse the effect of IKK-DN on osteoblast function as p65 is the active subunit of NF-kB which is located downstream of the IKK activation and cannot be inhibited by IKK-DN [9] [10] [11] [12] [13] . Using retroviral infection, we stably expressed p65 in Bglap2-IKK-DN cells, as determined by western blot analysis ( Fig. 3i) .
Overexpression of p65 strongly suppressed matrix mineralization in Bglap2-IKK-DN cells (Fig. 3i ). Real-time RT-PCR also confirmed that overexpression of p65 inhibited the expression of Runx2, Sp7, alkaline phosphatase (Alpl), Ocn, Ibsp and Col1a2 (Fig. 3j) . In contrast, overexpression of the c-Rel and RelB subunits of NF-kB in calvarial cells could not inhibit osteoblast differentiation and mineralization ( Supplementary Fig. 5 online) .
Inhibition of NF-jB lowers bone loss induced by ovariectomy
The elevated concentrations of proinflammatory cytokines in osteoporosis have been found to stimulate bone resorption and inhibit bone formation 5, 26 . Given that these cytokines potently activate NF-kB, we hypothesized that NF-kB activation secondary to sex steroid deficiency might inhibit osteoblast function in osteoporosis. To mimic the molecular pathogenesis of bone loss in postmenopausal osteoporosis in humans, the ovariectomy mouse model has been widely used to induce estrogen deficiency and bone loss. Because the bone structure and bone mineral density of adult Bglap2-IKK-DN mice were identical to those in WT mice, Bglap2-IKK-DN mice serve as an excellent model to test whether NF-kB activation promotes bone loss by inhibiting osteoblast function in osteoporosis.
We sham-operated or ovariectomized 3month-old WT mice and Bglap2-IKK-DN mice from two founder lines. mCT revealed that trabecular bones in vertebrae and femurs from WT mice were markedly lost after ovariectomy compared with sham-operated mice (Fig. 4a,b) . In contrast, far less bone loss was observed in Bglap2-IKK-DN mice after ovariectomy ( Fig. 4a,b) . Quantitative measurements indicated that whereas approximately 40% of BMD was lost in WT mice after ovariectomy, only 12% of BMD was lost in trabecular bone of femurs in Bglap2-IKK-DN mice after ovariectomy (Fig. 4c) . In vertebrae, whereas BMD was reduced by 40% in WT mice, BMD was only reduced by 20% in Bglap2-IKK-DN mice (Fig. 4d) . Similarly, the loss of bone volume was significantly prevented in Bglap2-IKK-DN mice compared with WT mice after ovariectomy (Fig. 4c,d) . Histological analysis also revealed that, whereas the trabecular bone mass was markedly depleted in WT mice, a considerable amount of the trabecular bone was retained in the bone marrow cavity of Bglap2-IKK-DN mice after ovariectomy (Fig. 4e) . To further confirm our results, we also performed ovariectomy in Col1a1-IKK-DN mice. Compared with WT mice, bone loss in Col1a1-IKK-DN mice was also substantially lower ( Supplementary Fig. 6 online) . Finally, we found that, although TNF treatment inhibited bone formation induced by bone morphogenetic proteins) in WT mice, the TNF-mediated inhibition of bone formation in Bglap2-IKK-DN mice was substantially lower ( Supplementary Fig. 7 online) .
NF-jB activation inhibits bone formation in osteoporosis
To explore the molecular mechanism by which inhibition of NF-kB prevents bone loss in osteoporosis, we first examined whether NF-kB is activated in osteoporosis using the antibodies specific for the active form of the NF-kB p65 subunit 20 . Using hemagglutinin (HA)-specific antibodies, we detected HA-tagged IKK-DN in osteoblasts of Bglap2-IKK-DN mice but not of WT mice (Fig. 5a) . Although there was weak staining of the active p65 in mature osteoblasts from Bglap2-IKK-DN mice after ovariectomy, there was intense active p65 staining in mature osteoblasts from WT mice after ovariectomy (Fig. 5a) . As a point of comparison, there was no active p65 staining in sham-operated mice (Fig. 5a) .
To examine whether the inhibition of NF-kB enhanced osteoblast activity, we measured serum OCN at 0, 1, 2, 4, 6 and 8 weeks after ovariectomy. Although there was a substantial increase in serum Ocn concentrations in both WT and Bglap2-IKK-DN mice 1 to 4 weeks after ovariectomy, we observed an even greater increase in serum OCN in Bglap2-IKK-DN mice 1 to 4 weeks after ovariectomy (Fig. 5b) . The serum OCN concentrations remained significantly higher in Bglap2-IKK-DN mice than in WT mice 8 weeks after ovariectomy (Fig. 5b) . Moreover, in vivo dynamic labeling revealed that bone formation rates 4 weeks after ovariectomy were significantly higher in Bglap2-IKK-DN mice compared to WT mice (Fig 5c) . Histological analysis showed that the inhibition of NF-kB in mature osteoblasts did not affect osteoblast differentiation (Fig. 5d ). There were no differences in osteoclast numbers between WT and Bglap2-IKK-DN mice after ovariectomy ( Fig. 5e) . Moreover, serum TRAP5b concentrations were increased to similar degrees in WT and Bglap2-IKK-DN mice after ovariectomy (Fig. 5f) .
NF-jB Inhibition promotes bone formation by inducing Fra-1
To explore the molecular mechanism through which NF-kB inhibition enhances bone formation, we screened multiple signaling pathways that are involved in bone matrix protein deposition. We found that c-Jun N-terminal kinase (JNK) activity in Bglap2-IKK-DN cells was higher than in WT cells 2 weeks after induction of osteoblast differentiation in vitro (Fig. 6a) . The induction of IKK-DN was associated with the appearance of increased JNK activities (Fig. 6a) .
In contrast, there were no substantial differences in p38 mitogenactivated protein kinase activities between Bglap2-IKK-DN and WT cells (Fig. 6b) . Previously, NF-kB was found to negatively regulate JNK activity, and inhibition of NF-kB leads to prolonged JNK activation [27] [28] [29] . Thus, increased JNK activities were probably due to the inhibition of NF-kB in differentiated osteoblasts. It is known that the activation of JNK stimulates activator protein (AP-1) transcription 29, 30 . Genetic studies established that several members of AP-1 family members such as Fra-1 (encoded by Fosl1) and FBJ murine osteosarcoma viral oncogene homolog B (FosB) are essential in bone formation after birth [31] [32] [33] . Thus, we first explored whether Fosl1 and Fosb were differentially induced in Bglap2-IKK-DN cells relative to WT cells. Real-time RT-PCR revealed that Fosl1 expression was significantly higher in Bglap2-IKK-DN cells compared with WT cells upon induction ( Fig. 6c) . Of note, the difference might be underestimated as a result of cell heterogeneicity in vitro. In contrast, RT-PCR showed that there was no difference in the expression of Fosb and the truncated DFosb isoform between Bglap2-IKK-DN cells and WT cells (Fig. 6d) . Additionally, other AP-1 family members, including the Jun, Junb, Jund and Fos were detected at similar levels in both Bglap2-IKK-DN cells and control cells (Fig. 6e) . Moreover, western blot analysis also confirmed that expression of Fra-1 proteins was enhanced in Bglap2-IKK-DN cells compared with control cells (Fig. 6a) . The JNK inhibitor SP600125 also inhibited the expression of Fra-1, suggesting that Fra-1 expression is dependent on JNK activation (Fig. 6f) .
To determine whether Fra-1 has a role in osteoblast function, we used a short hairpin RNA (shRNA) strategy to knock down Fosl1 expression by constructing two different shRNA constructs: shRNA Fosl1-1 and shRNA Fosl1-2, which target two different coding regions of Fosl1.
Whereas shRNA Fosl1-1 lowered Fra-1 amounts by only 20%, shRNA Fosl1-2 reduced Fra-1 levels by 90% in osteoblasts, as determined by western blot analysis (Fig. 6g) . Consistently, shRNA Fosl1-2 more substantially inhibited bone matrix mineralization of Bglap2-IKK-DN cells in vitro than shRNA Fosl1-1 (Fig. 6h) . Real-time RT-PCR revealed that shRNA Fosl1-2 substantially suppressed the expression of bone matrix genes, including Ocn, Ibsp and Col1a2 (Fig. 6i) . To further determine whether enhanced Fra-1 expression was responsible for preventing bone loss in ovariectomized mice, we also performed immunostaining to examine Fra-1 expression in osteoblasts in vivo. Whereas basal expression of Fra-1 was similar in both sham-operated WT and Bglap2-IKK-DN mice, we found intensive Fra-1 staining in osteoblasts localized on the bone surfaces of Bglap2-IKK-DN mice after ovariectomy relative to WT mice after ovariectomy (Fig. 6j) .
DISCUSSION
Postmenopausal osteoporosis is a common debilitating metabolic disease among the aged population and represents a major public health burden. There is a relative deficit in bone formation in osteoporosis [4] [5] [6] [7] [8] . Here we identified NF-kB as a crucial factor responsible for inhibiting bone formation in a model of osteoporosis. Suppression of NF-kB in differentiated osteoblasts prevents osteoporotic bone loss by maintaining osteoblast function. Considering the well established role of NF-kB in osteoclast activation and bone resorption, our results suggest that targeting NF-kB in treatments for osteoporosis and inflammatory bone disorders will not only suppress bone resorption but also promote bone formation, which is crucial for rebuilding bone mass. According to our immunostaining studies, NF-kB in differentiated osteoblasts is abnormally activated in ovariectomy-induced osteoporosis. There are two primary mechanisms that may promote NF-kB activation in differentiated osteoblasts. First, estrogen receptor has been found to directly inhibit NF-kB transcription in a liganddependent fashion by interacting with NF-kB 34 . Because estrogen receptor is expressed in osteoblasts, estrogen may negatively regulate NF-kB activities under physiological conditions. However, during the pathogenesis of osteoporosis, this negative regulation may be diminished due to lack of estrogen, resulting in the elevation of basal NF-kB activities in osteoblasts. Second, proinflammatory cytokines, including TNF, interleukin-1 (IL-1), IL-6 and IL-7, have been found to be highly expressed by T cells and other cells in osteoporosis 5 . These cytokines can potently stimulate NF-kB activities in osteoblasts. Previously, most studies focused on how proinflammatory cytokines activate NF-kB to induce osteoclast formation and activation 15 . However, it has long been known that proinflammatory cytokines also inhibit osteoblast differentiation and bone formation in osteoporosis, arthritis, periodontitis and multiple myeloma by unknown mechanims 5, 6, 26, 35 . Our results suggest that these cytokines activate NF-kB to suppress osteoblast function, thereby inhibiting bone formation. Our in vitro studies revealed that the inhibition of NF-kB leads to enhanced Fra-1 expression in differentiated osteoblasts. Previously, loss-and gain-of-function studies in mice have demonstrated that Fra-1 is an essential factor for bone matrix deposition or bone formation 31, 33 . However, although Fra-1 is a key target, it remains possible that NF-kB may regulate other molecules to inhibit bone formation. On the basis of our studies and other works on osteoclasts, we propose a new role of NF-kB in osteoporosis: activation of NF-kB due to sex steroid deficiency not only promotes osteoclast activation and bone resorption but also simultaneously inhibits osteoblast function, thus limiting the compensatory bone formation that maintains bone homeostasis ( Supplementary Fig. 7) .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
ONLINE METHODS
Cell culture. We isolated primary calvarial cells from newborn mice and cultured them in a-MEM (Invitrogen) with 10% FBS. To induce osteoblastic differentiation, we grew cells in differentiation-inducing medium containing 100 mg ml -1 ascorbic acid, 2 mM b-glycerophosphate and 1 mM dexamethasone for 1, 2 and 3 weeks. After induction, we fixed cells with 70% ethanol and stained with an alkaline phosphatase staining kit according to the manufacturer's protocol (Sigma-Aldrich). For detecting mineralization, we induced cells for 2 to 3 weeks, fixed them with 70% ethanol and stained them with 2% alizarin red (Sigma-Aldrich).
Western blot analysis, electrophoretic mobility shift assay and real-time reverse transcription-PCR. We performed western blot analysis and EMSA as described previously 20 . We used the following primary antibodies (sources in parentheses): polyclonal antibody to IkBa (Santa Cruz), polyclonal antibody to p65 (Rockland), monoclonal antibody to a-tubulin (Sigma) and polyclonal antibody to Runx-2 (Oncogene Research Products). We extracted total RNA with Trizol (Invitrogen). We synthesized 2-mg aliquots of RNAs with random hexamers and reverse transcriptase (Invitrogen). We performed the real-time PCR reactions using the QuantiTect SYBR Green PCR kit (Qiagen) and Icycler iQ Multi-color Real-time PCR Detection System. The primer sequences are listed in the Supplementary Methods online.
Generation of transgenic mice. We used the plasmid pGL647, which contains the Bglap2 promoter to specifically drive osteoblast-specific gene expression in vivo 23 . We subcloned human IKK-DN cDNA into pGL647. The fragments of Bglap2-IKK-DN transgene were purified and microinjected into (C57BL/6 Â SJL) F2 mouse oocytes, (Charles River Laboratories) and the oocytes were surgically transferred to pseudopregnant C57BL/6 dams by the University of Michigan Transgenic Animal Model Core. We screened the founders by PCR using mouse tail genomic DNA and confirmed them by Southern blot analysis. We bred two transgenic founder mice with C57BL/6 mice for six generations to obtain a defined genetic background. We ovariectomized 3-month-old transgenic and WT mice to induce osteoporosis. Two months after operation, we killed the mice and gathered their tibiae, femurs and vertebrae for histological and mCT analysis. We collected blood samples and isolated serums for serology. We measured serum TRAP5b with a mouse TRAP assay kit (SBA Sciences) and Ocn with an Ocn ELISA kit (Biomedical Technologies). All mouse protocols were approved by The University Committee on Use and Care of Animals at the University of Michigan, the Animal Research Committee at the University of California-Los Angeles or both.
Bone histological and morphological analysis. We stained skeletons from newborn pups with alizarin red and alcian blue as previously described 25 . For histological analyses, we killed mice at the ages of 2, 4 and 8 weeks and 6 months and fixed femurs and vertebrae in 10% neutral-buffered formalin. For immunostaining, we performed antigen retrieval by pressure cooking in a Decloaking chamber (Biocare Medical) in citrate buffer (2.1 M citric acid, pH 6.0) at 120 1C for 20 min. We incubated sections with polyclonal antibodies to Fra-1 (Santa Cruz; 1 in 100), polyclonal antibodies to the active form of p65 (Rockland Inc; 1 in 100), monoclonal and polyclonal antibodies to HA (1 in 100), and polyclonal antibodies to phosphorylated JNK (Cell Signaling; 1 in 200) at 4 1C overnight. We then incubated sections with horseradish perioxidase-labeled polymer for 30 min, detected the immunocomplexes with AEC + chromogen (Dako EnVision System) and counterstained with hematoxylin as described previously 20 . For examination of bone formation, we injected mice with calcein twice, with the injections 7 d apart, and killed them 2 d after the final injection. We isolated tibiae, fixed them in ethanol and embedded them in methyl methacrylate. We prepared 8-mm longitudinal sections with microtome. We evaluated sections by fluorescence or stained them with 1% toluidine blue or von Kossa reagents. For osteoclast detection, we stained the sections with TRAP activities using a leukocyte acid phosphatase staining kit (Sigma-Aldrich). We measured bone parameters of femurs, tibiae and vertebrae by computer-assisted histomorphometry using Image Pro Plus 4.5 (Media Cybernetics) and SPOT 4.0 software (Diagnostic Instruments). We set the microradiography unit to 80 kV and 100 mA and scanned specimens at an 8.93-m voxel resolution on an EVS Corporation mCT scanner, with a total of 667 slices per scan. We generated a three-dimensional reconstruction with GEMS MicroView software from the set of scans. We defined the regions of interest as the areas between 0.3 mm and 0.6 mm proximal to the growth plate in the distal femurs, in order to include the secondary trabecular spongiosa. In vertebral bodies, we selected a cylinder fitting in the whole central regions of the trabecular bone as the region of interest. We used a fixed threshold (600) to extract the mineralized bone phase and actual bone volume and calculated BMD.
Statistical analyses. We presented data as means ± s.d. and determined statistic significance by Student's t test. We considered a P value o 0.05 statistically significant.
